

XIFAXAN has been proven to reduce two risks associated with overt HE

HE = hepatic encephalopathy.

In a clinical study, adults with a history of overt HE took one XIFAXAN 550 mg tablet twice daily for 6 months (n=140) or placebo (n=159). 91% of patients took lactulose at the same time. The results were:



Xifaxan group – 22% reported breakthrough HE episodes Placebo group – 46% reported breakthrough HE episodes



Xifaxan group -14% of patients had a hospitalization involving HE Placebo group -23% of patients had a hospitalization involving HE

Talk to your doctor to see if XIFAXAN is right for you

INDICATION

XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults.

IMPORTANT SAFETY INFORMATION

XIFAXAN is not for everyone. Do not take XIFAXAN if you have a known hypersensitivity to rifaximin, any of the rifamycin antimicrobial
agents, or any of the components in XIFAXAN.

Please see additional Important Safety Information on the following page and click here for full Prescribing Information.

How to take XIFAXAN



Take one 550 mg tablet of **XIFAXAN** twice daily



Take **XIFAXAN**with or
without food





Take **XIFAXAN**as long as your
healthcare provider
recommends

Cifaxar

How to save on XIFAXAN

Eligible[†] patients with commercial insurance covering XIFAXAN may pay as little as \$0 for their XIFAXAN prescription.

tPatient is not eligible if he/she participates in or seeks reimbursement or submits a claim for reimbursement to any federal or state healthcare program with prescription drug coverage, such as Medicaid, Medicare, Medigap, VA, DOD, TRICARE, or any similar federal or state health care program (each a Government Program), or where prohibited by law. Patient must be enrolled in, and must seek reimbursement from or submit a claim for reimbursement to, a commercial insurance plan.

Offer excludes full cash-paying patients. Maximum benefits and other restrictions apply.





- If you take antibiotics, like XIFAXAN, there is a chance you could experience diarrhea caused by an overgrowth of bacteria (*C. difficile*). This can cause symptoms ranging in severity from mild diarrhea to life-threatening colitis. Contact your healthcare provider if your diarrhea does not improve or worsens.
- Talk to your healthcare provider before taking XIFAXAN if you have severe hepatic (liver) impairment, as this may cause increased effects of the medicine.
- Tell your healthcare provider if you are taking drugs called P-glycoprotein and/or OATPs inhibitors (such as cyclosporine) because using these drugs with XIFAXAN may lead to an increase in the amount of XIFAXAN absorbed by your body.
- In clinical studies, the most common side effects for XIFAXAN were:
 - HE: Peripheral edema (swelling, usually in the ankles or lower limbs), constipation, nausea (feeling sick to your stomach), fatigue (feeling tired), insomnia (trouble sleeping), ascites (a buildup of fluid in the abdomen), dizziness, urinary tract infection, anemia (low red blood cell levels), and itching
- XIFAXAN may affect warfarin activity when taken together. Tell your healthcare provider if you are taking warfarin because the dose of warfarin may need to be adjusted to maintain proper blood-thinning effect.
- If you are pregnant, planning to become pregnant, or nursing, talk to your healthcare provider before taking XIFAXAN because XIFAXAN may cause harm to an unborn baby or nursing infant.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For product information, adverse event reports, and product complaint reports, please contact:

Salix Product Information Call Center • Phone: 1-800-321-4576 • Fax: 1-510-595-8183 • Email: salixmc@dlss.com

Please see additional Important Safety Information on the previous page and click here for full <u>Prescribing Information</u>.



Salix Pharmaceuticals

400 Somerset Corporate Blvd., Bridgewater, NJ 08807

The XIFAXAN 550 mg product and the XIFAXAN trademark are licensed by Alfasigma S.p.A.

to Salix Pharmaceuticals or its affiliates.

© 2024 Salix Pharmaceuticals or its affiliates.

XIF.0161.USA.20V3.0